CDC Releases 2018 Children, Adolescents and Adults Immunization Schedules

PUBLISHED: Feb 8, 2018
Relevant to: Ambulatory Care, Critical Access Hospitals, Home Health, Hospitals, Long Term Care, Medical Office, Pharmacy, Rural Health Clinics

The US Centers for Disease Control and Prevention (CDC) has released the 2018 Children, Adolescents and Adults Immunization Schedules. The Advisory Committee on Immunization Practices (ACIP) recommendations include several changes from the 2017 immunization schedules and those changes are summarized below.

Children and Adolescents:

  • Poliovirus:
    • The inactivated poliovirus rows of the catch-up schedule have been edited to clarify the catch-up recommendations for children 4 years of age and older.
    • The poliovirus vaccine footnote was revised to include updated guidance for persons who received oral polio vaccine as part of their vaccination series.
  • Influenza:
    • The influenza vaccine footnote has been updated to indicate that LAIV should not be used during the 2017–2018 influenza season. A reference link to the 2017-2018 season influenza recommendations has been added.
  • Measles, mumps, and rubella::
    • The measles, mumps, and rubella (MMR) footnote was updated to include guidance regarding the use of a 3rd dose of mumps-containing vaccine during a mumps outbreak.
  • Rotavirus:
    • The maximum ages for the first and last doses of the rotavirus series have been added to the rotavirus vaccine row of the catch-up schedule.
  • Pneumococcal:
    • Clarification that in some situations children with heart disease/chronic lung disease, chronic liver disease, and diabetes may be recommended to receive an additional dose of vaccine.


  • Tdap or Td:
    • Td/Tdap” has been replaced by “Tdap or Td” on Figures 1 and 2 and the text in the indication bar has been revised to “1 dose Tdap, then Td booster every 10 years.
  • MMR:
    • Administer 1 dose of MMR to adults who previously received less than or equal to (≤)2 doses of mumps-containing vaccine and are identified by a public health authority to be at increased risk during a mumps outbreak.
    • The text in the indication bar for Figure 1 for MMR has been changed to “1 or 2 doses depending on indication (if born in 1957 or later)."
  • Zoster:
    • Administer 2 doses of recombinant zoster vaccine (RZV) (Shingrix) 2 to 6 months apart to adults aged 50 years or older regardless of past episode of herpes zoster or receipt of zoster vaccine live (ZVL) (Zostavax).
    • Administer 2 doses of RZV 2 to 6 months apart to adults who previously received ZVL at least 2 months after ZVL.
    • For adults aged 60 years or older, administer either RZV or ZVL (RZV is preferred).
    • “ZVL” has replaced the term “HZV” (herpes zoster vaccine) that was used in past adult immunization schedules to refer to the live zoster vaccine. A row for RZV was added above the row for ZVL and a dashed line was used to separate RZV and ZVL rows to denote that the 2 zoster vaccines are recommended for the same purpose.
  • HPV:
    • In Figure 1, the text in the indication bars for HPV vaccine for females and males has been revised to “2 or 3 doses depending on age at series initiation.”
  • MenACWY:
    • In figures 1 and 2, the text in the indication bar for MenACWY (serogroups A, C, W, and Y meningococcal vaccine) has been revised to “1 or 2 doses depending on indication, then booster every 5 years if risk remains.”
    • MPSV4 (4-valent meningococcal polysaccharide vaccine) is no longer available and has been removed from the adult immunization schedule.

Included with today’s notice are example policies that will be of interest to vaccine providers as well as links to the updated 2018 immunization schedules.

Want to read the full alert and receive alert emails?

Browse Additional Alerts